News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Harry P. Erba, MD, PhD, Duke University School of Medicine

Articles by Harry P. Erba, MD, PhD, Duke University School of Medicine

FLT3 Triplet Regimens for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Venetoclax in AML: Safety Profile

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Optimal Use of Venetoclax in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

VIALE Studies in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3 Genetic Alterations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer